Reply to M. Uccello et al

Affiliations

Comment

Sharlene Gill. J Clin Oncol. 2017.

. 2017 Apr 20;35(12):1371.

doi: 10.1200/JCO.2016.71.3883. Epub 2017 Jan 23.

No abstract available

Comment on

PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, Zalewski P, Do T, Cano P, Lam WYH, Dowden S, Grassin H, Stewart J, Moore M. Gill S, et al. J Clin Oncol. 2016 Nov 10;34(32):3914-3920. doi: 10.1200/JCO.2016.68.5776. Epub 2016 Sep 30. J Clin Oncol. 2016. PMID: 27621395 Clinical Trial.
Second-Line Combination Therapies in Pancreatic Cancer: Where Are We Now?
Uccello M, Moschetta M, Arkenau HT. Uccello M, et al. J Clin Oncol. 2017 Apr 20;35(12):1370-1371. doi: 10.1200/JCO.2016.71.0921. Epub 2017 Jan 23. J Clin Oncol. 2017. PMID: 28113022 No abstract available.